162 related articles for article (PubMed ID: 35925880)
1. Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.
Li J; Liu T; Song Y; Wang M; Liu L; Zhu H; Li Q; Lin J; Jiang H; Chen K; Zhao K; Wang M; Zhou H; Lin H; Luo C
J Med Chem; 2022 Aug; 65(16):11034-11057. PubMed ID: 35925880
[TBL] [Abstract][Full Text] [Related]
2. Discovery of HyT-Based Degraders of CDK9-Cyclin T1 Complex.
Lin R; Yang J; Liu T; Wang M; Ke C; Luo C; Lin J; Li J; Lin H
Chem Biodivers; 2023 Aug; 20(8):e202300769. PubMed ID: 37349855
[TBL] [Abstract][Full Text] [Related]
3. Cyclin K inhibits HIV-1 gene expression and replication by interfering with cyclin-dependent kinase 9 (CDK9)-cyclin T1 interaction in Nef-dependent manner.
Khan SZ; Mitra D
J Biol Chem; 2011 Jul; 286(26):22943-54. PubMed ID: 21555514
[TBL] [Abstract][Full Text] [Related]
4. CDK9 has the intrinsic property to shuttle between nucleus and cytoplasm, and enhanced expression of cyclin T1 promotes its nuclear localization.
Napolitano G; Licciardo P; Carbone R; Majello B; Lania L
J Cell Physiol; 2002 Aug; 192(2):209-15. PubMed ID: 12115727
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo.
Majello B; Napolitano G; Giordano A; Lania L
Oncogene; 1999 Aug; 18(32):4598-605. PubMed ID: 10467404
[TBL] [Abstract][Full Text] [Related]
6. Interaction between cyclin T1 and SCF(SKP2) targets CDK9 for ubiquitination and degradation by the proteasome.
Kiernan RE; Emiliani S; Nakayama K; Castro A; Labbé JC; Lorca T; Nakayama Ki K; Benkirane M
Mol Cell Biol; 2001 Dec; 21(23):7956-70. PubMed ID: 11689688
[TBL] [Abstract][Full Text] [Related]
7. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription.
O'Keeffe B; Fong Y; Chen D; Zhou S; Zhou Q
J Biol Chem; 2000 Jan; 275(1):279-87. PubMed ID: 10617616
[TBL] [Abstract][Full Text] [Related]
8. Discovery of
Wang M; Lin R; Li J; Suo Y; Gao J; Liu L; Zhou L; Ni Y; Yang Z; Zheng J; Lin J; Zhou H; Luo C; Lin H
J Med Chem; 2023 Apr; 66(7):4932-4951. PubMed ID: 36930701
[TBL] [Abstract][Full Text] [Related]
9. Functional interaction between cyclin T1/cdk9 and Puralpha determines the level of TNFalpha promoter activation by Tat in glial cells.
Darbinian N; Sawaya BE; Khalili K; Jaffe N; Wortman B; Giordano A; Amini S
J Neuroimmunol; 2001 Dec; 121(1-2):3-11. PubMed ID: 11730934
[TBL] [Abstract][Full Text] [Related]
10. The CDK9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP.
Shiozaki Y; Okamura K; Kohno S; Keenan AL; Williams K; Zhao X; Chick WS; Miyazaki-Anzai S; Miyazaki M
J Biol Chem; 2018 Nov; 293(44):17008-17020. PubMed ID: 30209133
[TBL] [Abstract][Full Text] [Related]
11. Functional inactivation of Cdk9 through oligomerization chain reaction.
Napolitano G; Mazzocco A; Fraldi A; Majello B; Lania L
Oncogene; 2003 Jul; 22(31):4882-8. PubMed ID: 12894230
[TBL] [Abstract][Full Text] [Related]
12. Catalytic activity of Cdk9 is required for nuclear co-localization of the Cdk9/cyclin T1 (P-TEFb) complex.
Napolitano G; Majello B; Lania L
J Cell Physiol; 2003 Oct; 197(1):1-7. PubMed ID: 12942536
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy.
Wu T; Zhang Z; Gong G; Du Z; Xu Y; Yu S; Ma F; Zhang X; Wang Y; Chen H; Wu S; Xu X; Qiu Z; Li Z; Wu H; Bian J; Wang J
Eur J Med Chem; 2023 Nov; 260():115774. PubMed ID: 37672930
[TBL] [Abstract][Full Text] [Related]
14. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.
Gordon V; Bhadel S; Wunderlich W; Zhang J; Ficarro SB; Mollah SA; Shabanowitz J; Hunt DF; Xenarios I; Hahn WC; Conaway M; Carey MF; Gioeli D
Mol Endocrinol; 2010 Dec; 24(12):2267-80. PubMed ID: 20980437
[TBL] [Abstract][Full Text] [Related]
15. Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1.
Feichtinger S; Stamminger T; Müller R; Graf L; Klebl B; Eickhoff J; Marschall M
J Gen Virol; 2011 Jul; 92(Pt 7):1519-1531. PubMed ID: 21450947
[TBL] [Abstract][Full Text] [Related]
16. Targeting cyclin-dependent kinase 9 in cancer therapy.
Shen YL; Wang YM; Zhang YX; Ma SJ; Yang LH; Zhao CG; Huang XY
Acta Pharmacol Sin; 2022 Jul; 43(7):1633-1645. PubMed ID: 34811514
[TBL] [Abstract][Full Text] [Related]
17. The CDK9-associated cyclins T1 and T2 exert opposite effects on HIV-1 Tat activity.
Napolitano G; Licciardo P; Gallo P; Majello B; Giordano A; Lania L
AIDS; 1999 Aug; 13(12):1453-9. PubMed ID: 10465067
[TBL] [Abstract][Full Text] [Related]
18. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
19. Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs.
Zeng Y; Xiao J; Xu Y; Wei F; Tian L; Gao Y; Chen Y; Hu Y
J Med Chem; 2023 Sep; 66(18):12877-12893. PubMed ID: 37671907
[TBL] [Abstract][Full Text] [Related]
20. Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation.
Ivanov D; Kwak YT; Nee E; Guo J; García-Martínez LF; Gaynor RB
J Mol Biol; 1999 Apr; 288(1):41-56. PubMed ID: 10329125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
